Adult Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Comparison of Remission Rate and Leukemic Stem Cell Changes Among Patients With Newly Diagnosed Adult ALL With Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen.
This trial is a multicenter prospective, open, non-intervention clinical study. 200 patients with newly diagnosed adult ALL who underwent induction remission with the VDCLD regimen containing PLD and DNR, respectively,were plan to enrolled in this study to evaluate the CR rate and the level of myeloid leukemia stem cells in the first course of chemotherapy with two regimens; and to evaluate the safety of the two induction chemotherapy regimens.
Subjects will receive one of two treatment regimens:
Group A: intravenous drip of liposomal doxorubicin 36 mg/m2, d1、d15，1h； VCR 1.4mg/m2.d
d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28
ivdrip，once every 28days.
Group B: intravenous drip of DNR45mg/m2，d d1～3，1h；VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX
800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip，once every 28days.
The primary endpoint is complete remission after the first course treatment of induced
remission chemotherapy, to evaluated the ratio of CR patients after the first course of
chemotherapy with PLD and DNR VDCLD regimens.The secondary endpoint is to evaluate the
changes of myeloid leukemia stem cells in patients before and after induction of VDCLD with
PLD and DNR respectively.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT00188084 -
Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia
|
N/A | |
| Recruiting |
NCT02072785 -
Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia
|
Phase 3 | |
| Completed |
NCT01484015 -
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
|
Phase 1 | |
| Recruiting |
NCT03564704 -
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
|
Phase 2/Phase 3 | |
| Completed |
NCT00537030 -
Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia
|
N/A | |
| Active, not recruiting |
NCT02159495 -
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
|
Phase 1 | |
| Completed |
NCT01251575 -
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
|
Phase 2 |